Respiratory and Antinociceptive Effects of Nociceptin Receptor–µ-Opioid Receptor Agonist Cebranopadol versus Full Opioid Receptor Agonist Oxycodone: A Comparison in Healthy Volunteers
The primary endpoint showed separation between the respiratory effects of cebranopadol and oxycodone, with 25% less respiratory depression at equianalgesia, as observed in the pharmacokinetic/pharmacodynamic analysis.
Authors
- J. V. Hackworth
- Geert Jan Groeneveld (ORCID: https://orcid.org/0000-0002-4655-6667)
- Joseph C. Grieco (ORCID: https://orcid.org/0000-0002-7680-3008)
- Monique van Velzen (ORCID: https://orcid.org/0000-0002-0289-6432)
- Elise Sarton (ORCID: https://orcid.org/0009-0007-4403-3815)
- Rutger van der Schrier (ORCID: https://orcid.org/0000-0003-1422-3830)
- Erik Olofsen
- Albert Dahan (ORCID: https://orcid.org/0000-0003-3161-3945)
- Marieke Niesters (ORCID: https://orcid.org/0009-0002-2822-7509)
- Simone Jansen (ORCID: https://orcid.org/0000-0002-1175-5877)
- Laurence Moss (ORCID: https://orcid.org/0000-0001-6182-0553)
- Marc L. Lesnick
Institutions
- Outcomes Research Consortium (US)
- Leiden University Medical Center (NL)
- Erasmus MC (NL)
- DH Consultancy BVBA (Belgium) (BE)
- PharmaSeq (United States) (US)
- Centre for Human Drug Research (NL)
- Amsterdam University Medical Centers (NL)
- Janssen (Netherlands) (NL)
- Tris Pharma (United States) (US)
Publication Details
- Journal
- Anesthesiology
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1097/aln.0000000000005894
- Primary Topic
- Pain Management and Opioid Use
- Type
- article
- Field-Weighted Citation Impact
- 0.00